Ublituximab

A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
024620132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
INTRODUCTION Non-Hodgkin lymphoma (NHL) is the most common adult hematologic malignancy. Conventional methods of treatment are… (More)
Is this relevant?
2017
2017
Over 50 investigational monoclonal antibody (mAb) therapeutics are currently undergoing evaluation in late-stage clinical studies… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2017
2017
Ibrutinib is effective in patients with chronic lymphocytic leukaemia (CLL); however, treatment resistance remains a problem… (More)
  • figure 1
  • table I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
This phase 1/2 study evaluated the safety, pharmacokinetic behavior and anti-tumour activity of ublituximab, a unique type I… (More)
  • figure 1
  • table I
  • table II
  • table III
  • figure 2
Is this relevant?
2017
2017
1008 Saturday June 3, 1:15 PM to 4:15 PM; Hall D1 Ian Flinn, Richard van der Jagt, Julie E. Chang, Peter Wood, Tim E. Hawkins… (More)
Is this relevant?
Review
2017
Review
2017
The anti-CD20 antibodies represent a major advancement in the therapeutic options available for chronic lymphocytic leukemia. The… (More)
Is this relevant?
2016
2016
Unconjugated monoclonal antibodies (mAbs) are an important component of effective combination therapies for chronic lymphocytic… (More)
  • figure 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
We thank Bernd Baumann for his advice in the electrophoretic mobility shift assay and Stefanie Dannenmann and Florian Blum (Core… (More)
  • table 1
  • figure 1
Is this relevant?
2013
2013
PURPOSE Primary cerebral lymphoma (PCL) and primary intraocular lymphoma (PIOL) belong to the systemic diffuse large B-cell… (More)
Is this relevant?